贝伐珠单抗联合安罗替尼对晚期非小细胞肺癌患者肿瘤 标志物及免疫状态的影响  

The Effect of Bevacizumab Combined with Anlotinib on Tumor Markers and Immune Status in Patients with Advanced Non-Small Cell Lung Cancer

作　　者：孙彩云 焦阳 何亚楠 SUN Cai-yun;JIAO Yang;HE Ya-nan(Kaifeng Cancer Hospital,Kaifeng,Henan 475003,China)

机构地区：[1]开封市肿瘤医院,河南开封475003

出　　处：《黔南民族医专学报》2025年第1期51-55,共5页Journal of Qiannan Medical College for Nationalities

摘　　要：目的:探讨晚期非小细胞肺癌(NSCLC)患者采用贝伐珠单抗联合安罗替尼治疗对肿瘤标志物与免疫状态的影响。方法:选择2022年1月至2023年12月本院92例晚期NSCLC患者,按治疗方法分为对照组(46例)和观察组(46例),观察组采用贝伐珠单抗联合安罗替尼进行治疗,对照组则采用安罗替尼进行治疗。比较两组肿瘤标志物、免疫状态、生存质量及不良反应情况。结果:治疗后观察组患者CYFRA21-1、CA125、CEA、VEGF水平均比对照组低;治疗后观察组CD3+、CD4+、CD4+/CD8+水平均比对照组高,CD8+水平比对照组低;治疗后,观察组社会、生理、环境、心理维度得分均比对照组高(P<0.05);治疗期间两组不良反应发生率无明显差异(χ^(2)=0.050,P=0.822)。结论:晚期NSCLC患者采用贝伐珠单抗联合安罗替尼治疗可降低肿瘤标志物水平,改善免疫状态,提高生存质量,且不增加不良反应情况。Objective:To explore the effects of bevacizumab combined with anlotinib treatment on tumor markers and immune status in patients with advanced non-small cell lung cancer(NSCLC).Methods:92 patients with advanced NSCLC were selected from Kaifeng Cancer Hospital from January 2022 to December 2023.They were divided into a control group(46 cases)and an observation group(46 cases)according to the treatment method.The observation group was treated with bevacizumab combined with anlotinib,while the control group was treated with anlotinib.Compare two groups of tumor markers,immune status,quality of life,and adverse reactions.Results:After treatment,the levels of CYFRA21-1,CA125,CEA,and VEGF in the observation group were lower than those in the control group;After treatment,the levels of CD3+,CD4+,CD4+/CD8+in the observation group were higher than those in the control group,while the levels of CD8+were lower than those in the control group;After treatment,the observation group had higher scores in social,physiological,environmental,and psychological dimensions than the control group(P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups during the treatment period(x^(2)=0.050,P=0.822).Conclusion:Treatment with bevacizumab combined with anlotinib in advanced NSCLC patients can reduce tumor marker levels,improve immune status,improve quality of life,and do not increase the incidence of adverse reactions.

关 键 词：非小细胞肺癌 贝伐珠单抗 安罗替尼 肿瘤标志物 免疫状态 

分 类 号：R734.2[医药卫生—肿瘤]